Theranexus (EPA:ALTHX) | WebDisclosure

PRESS RELEASE

published on 07/03/2024 at 07:30, 1 year 6 months ago

THERANEXUS, LE CENTRE DE RECHERCHE EN NEUROSCIENCES DE LYON ET LE CERMEP, LAURÉATS DU PROJET " PACTE DE RECHERCHE 2024 " DE LA REGION AUVERGNE-RHÔNE-ALPES
Theranexus, CRNL, and CERMEP win 'Pacte de recherche 2024' project in Auvergne-Rhône-Alpes to develop new neuroimaging tools for rare neurological diseases treatment

Theranexus Rare Neurological Diseases Neuroimaging CRNL CERMEP
PRESS RELEASE

published on 07/03/2024 at 07:30, 1 year 6 months ago

THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION
Theranexus, Lyon Neuroscience Research Center, and CERMEP win research pact project 'IMASO' in Auvergne-Rhône-Alpes Region for preclinical neuroimaging in rare neurological diseases

Theranexus Neurological Diseases Research Pact Auvergne-Rhône-Alpes Region Preclinical Neuroimaging
BRIEF

published on 06/06/2024 at 07:35, 1 year 7 months ago

Theranexus et BBDF annoncent des résultats positifs à 18 mois pour Batten-1 dans une étude de phase 1/2

Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
BRIEF

published on 06/06/2024 at 07:35, 1 year 7 months ago

Theranexus and BBDF Announce Positive Results at 18 Months for Batten-1 in Phase 1/2 Study

Theranexus Batten-1 BBDF Batten Disease Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 1 year 7 months ago

Theranexus et BBDF confirment les résultats positifs à 18 mois de Batten-1 dans l'étude de phase 1/2 sur les neurofilaments, un biomarqueur de la mort neuronale
Theranexus et BBDF confirment les résultats positifs à 18 mois de l'étude de phase 1/2 sur les neurofilaments, biomarqueur de la mort neuronale, concernant le médicament Batten-1 dans la maladie de Batten (CLN3)

Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
PRESS RELEASE

published on 06/06/2024 at 07:30, 1 year 7 months ago

Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death
Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential

Theranexus Batten-1 BBDF CLN3 Batten Disease Neurofilament Light Chains
BRIEF

published on 05/02/2024 at 07:35, 1 year 8 months ago

Theranexus dévoile son document d'enregistrement universel pour 2023

2023 Biopharmaceutique Document D'Enregistrement Universel Theranexus Maladies Neurologiques Rares
BRIEF

published on 05/02/2024 at 07:35, 1 year 8 months ago

Theranexus unveils its universal registration document for 2023

2023 Biopharmaceutical Universal Registration Document Theranexus Rare Neurological Diseases
PRESS RELEASE

published on 05/02/2024 at 07:30, 1 year 8 months ago

MISE A DISPOSITION DU DOCUMENT D'ENREGISTREMENT UNIVERSEL 2023
Theranexus annonce le dépôt de son document d'enregistrement universel pour l'exercice 2023, disponible sur son site. Theranexus se spécialise dans le traitement des maladies neurologiques rares

Biopharmaceutique Theranexus Maladies Neurologiques Rares Dépôt Document D'enregistrement Universel Neurones Et Cellules Gliales
BRIEF

published on 04/29/2024 at 18:25, 1 year 9 months ago

Theranexus Reports 2023 Full-Year Results and Details Recent Progress

2023 Financial Results Theranexus Rare Neurological Diseases PickASO Project Batten Disease

Published on 01/31/2026 at 03:15, 1 day 8 hours ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 1 day 9 hours ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 1 day 9 hours ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 1 day 11 hours ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 1 day 12 hours ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 15:54, 19 hours 25 minutes ago

EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 22 hours 54 minutes ago

JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 8 hours ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 13 hours ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 15 hours ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026

View all EQS

Published on 01/30/2026 at 18:40, 1 day 16 hours ago

ICADE - Bilan semestriel du contrat de liquidite
Published on 01/30/2026 at 18:01, 1 day 17 hours ago

Emova Group - Résultats annuels 2024/25
Published on 01/30/2026 at 17:45, 1 day 17 hours ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 17:45, 1 day 17 hours ago

Schneider Electric lance une augmentation de capital réservée aux salariés
Published on 01/30/2026 at 08:30, 2 days 2 hours ago

Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés

View all LES ECHOS COMFI WIRE

News